Search results with tag "Gonal f"
PRODUCT INFORMATION GONAL-f PEN Recombinant ... - …
www.medsafe.govt.nzVersion: A008-1116 2 Supersedes: A007-0414 Following subcutaneous administration, the absolute bioavailability is about 70%. Following repeated administration, GONAL-f accumulates 3-fold at steady state within 3 – 4 days.
Gonal-f - Food and Drug Administration
www.accessdata.fda.govNDA 20-378/S-015 Page 6 Pharmacodynamics Following daily subcutaneous administration of 150 IU of Gonal-f® for 7 days in healthy female volunteers, serum inhibin and estradiol, and total follicular volume responded as a function of time,
Gonal-f® RFF Pen - Food and Drug Administration
www.accessdata.fda.govperitoneal cavity, thorax, and potentially, the pericardium. The early warning signs of development of OHSS are severe pelvic pain, nausea, vomiting, and weight gain. The following symptomatology has been seen with cases of OHSS: abdominal pain, abdominal distension, gastrointestinal symptoms including nausea, vomiting and diarrhea, severe